¾ÅÉ«

NEW YORK, NY, November 7, 2018 ¨C , a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced that Symphogen has selected ¾ÅÉ«¡¯s eTMF and supporting TMF services to centralize and streamline operations for current and future studies. 

Based in Copenhagen, Denmark, Symphogen is a private, late-stage clinical oncology-focused company with a novel and differentiated antibody mixture pipeline. Specifically, they are pioneering the application of mAb mixtures as an innovative approach to cancer therapy. As the company progresses with their clinical programs, including an anticipated Phase 3 study, Symphogen will leverage Trial Interactive¡¯s eTMF and TMF services for greater control of TMF quality and health, and to support scalability throughout their current growth. Among these organizational goals, Symphogen is also focused on enhancing CRO/sponsor collaboration with a secure environment to manage multiple roles and relationships.

The Trial Interactive e-clinical platform was designed by clinical professionals, for clinical professionals. It is used by pharmaceutical, biotechnology, and CRO companies to streamline product development lifecycles in a secure, 21 CFR Part 11-compliant environment. By offering a fully integrated experience, Trial Interactive improves speed and quality across site identification, site selection, personnel training, study start-up, and site activation, through eTMF management and closeout. The Trial Interactive platform delivers nuanced, clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.

Michael Smyth, Division President of ¾ÅÉ« Life Sciences ¾ÅÉ«, stated, ¡°Our aim is to enable growth for our clients and their clinical teams by providing leading technology and expert-driven services. Symphogen¡¯s initiative to bring their eTMF system and management in-house is a perfect application of our e-clinical solutions that will have a significant benefit for their team and workflows.¡± 

¾ÅÉ« President and CEO, Phil Shawe, added, ¡°The work that Symphogen does for cancer patients is critically important, and it¡¯s rewarding to know that our technology and services play a role in helping them bring potentially life-changing treatments to market in the most efficient manner possible.¡±

About Trial Interactive
¾ÅÉ«¡¯s Trial Interactive solution provides a collaborative, web-based platform for clinical development that enables sponsors, CROs, IRBs, and other vendors to maintain and update clinical trial documentation in a secure online environment, adhering to global regulatory requirements. With fully searchable solutions including investigator portals, Trial Interactive streamlines study timelines and reduces the administrative burdens of global clinical trials. As part of ¾ÅÉ«¡¯s Life Sciences division, Trial Interactive is dedicated to working with clients on a global, collaborative level, supporting a wide range of requirements including e-feasibility, study start-up, eTMF review/reconciliation, mobile applications, learning management and document management systems, investigator portals, pharmacovigilance and safety management, and endpoint adjudication. For more information on Trial Interactive, please contact info@trialinteractive.com or +1 212.400.8848, or visit www.trialinteractive.com.

About ¾ÅÉ«
is the world¡¯s largest provider of and  for global business. From offices in over 90 cities on six continents, ¾ÅÉ« offers a full range of services in 170+ languages to clients worldwide. More than 4,000 global organizations employ ¾ÅÉ«¡¯s  Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, ¾ÅÉ« is fully  and  certified. ¾ÅÉ« has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at .